The global healthcare group Bupa, experienced rapid growth in markets as diverse as Saudi Arabia, Hong Kong and Chile. It continues to make acquisitions across emerging markets, as well as launching new healthcare insurance products and distribution agreements. Global sales rose 7% to £4,916m from the first half of 2014, at constant exchange rates (CER), or 3% taken at actual exchange rates (AER). Underlying profit before taxation hit £253.3m, an increase of 2% at CER, or a fall of 3% at AER. In a wide-ranging interview, CEO Stuart Fletcher, spoke to Healthcare Nova about the results and Bupa’s future plans.